Cargando…

LncRNA UCA1 in anti-cancer drug resistance

The pivotal role of the long non-coding RNA (lncRNA) urothelial carcinoma associated 1 (UCA1) in anti-cancer drug resistance has been confirmed in many cancers. Overexpression of lncRNA UCA1 correlates with resistance to chemotherapeutics such as cisplatin, gemcitabine, 5-FU, tamoxifen, imatinib and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haohao, Guan, Zhonghai, He, Kuifeng, Qian, Jiong, Cao, Jiang, Teng, Lisong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610032/
https://www.ncbi.nlm.nih.gov/pubmed/28969100
http://dx.doi.org/10.18632/oncotarget.18344
_version_ 1783265715461029888
author Wang, Haohao
Guan, Zhonghai
He, Kuifeng
Qian, Jiong
Cao, Jiang
Teng, Lisong
author_facet Wang, Haohao
Guan, Zhonghai
He, Kuifeng
Qian, Jiong
Cao, Jiang
Teng, Lisong
author_sort Wang, Haohao
collection PubMed
description The pivotal role of the long non-coding RNA (lncRNA) urothelial carcinoma associated 1 (UCA1) in anti-cancer drug resistance has been confirmed in many cancers. Overexpression of lncRNA UCA1 correlates with resistance to chemotherapeutics such as cisplatin, gemcitabine, 5-FU, tamoxifen, imatinib and EGFR-TKIs, whereas lncRNA UCA1 knockdown restores drug sensitivity. These studies highlight the potential of lncRNA UCA1 as a diagnostic and prognostic biomarker, and a therapeutic target in malignant tumors. In this review, we address the role of lncRNA UCA1 in anti-cancer drug resistance and discuss its potential in future clinical applications.
format Online
Article
Text
id pubmed-5610032
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56100322017-09-29 LncRNA UCA1 in anti-cancer drug resistance Wang, Haohao Guan, Zhonghai He, Kuifeng Qian, Jiong Cao, Jiang Teng, Lisong Oncotarget Review The pivotal role of the long non-coding RNA (lncRNA) urothelial carcinoma associated 1 (UCA1) in anti-cancer drug resistance has been confirmed in many cancers. Overexpression of lncRNA UCA1 correlates with resistance to chemotherapeutics such as cisplatin, gemcitabine, 5-FU, tamoxifen, imatinib and EGFR-TKIs, whereas lncRNA UCA1 knockdown restores drug sensitivity. These studies highlight the potential of lncRNA UCA1 as a diagnostic and prognostic biomarker, and a therapeutic target in malignant tumors. In this review, we address the role of lncRNA UCA1 in anti-cancer drug resistance and discuss its potential in future clinical applications. Impact Journals LLC 2017-06-02 /pmc/articles/PMC5610032/ /pubmed/28969100 http://dx.doi.org/10.18632/oncotarget.18344 Text en Copyright: © 2017 Wang et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Review
Wang, Haohao
Guan, Zhonghai
He, Kuifeng
Qian, Jiong
Cao, Jiang
Teng, Lisong
LncRNA UCA1 in anti-cancer drug resistance
title LncRNA UCA1 in anti-cancer drug resistance
title_full LncRNA UCA1 in anti-cancer drug resistance
title_fullStr LncRNA UCA1 in anti-cancer drug resistance
title_full_unstemmed LncRNA UCA1 in anti-cancer drug resistance
title_short LncRNA UCA1 in anti-cancer drug resistance
title_sort lncrna uca1 in anti-cancer drug resistance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610032/
https://www.ncbi.nlm.nih.gov/pubmed/28969100
http://dx.doi.org/10.18632/oncotarget.18344
work_keys_str_mv AT wanghaohao lncrnauca1inanticancerdrugresistance
AT guanzhonghai lncrnauca1inanticancerdrugresistance
AT hekuifeng lncrnauca1inanticancerdrugresistance
AT qianjiong lncrnauca1inanticancerdrugresistance
AT caojiang lncrnauca1inanticancerdrugresistance
AT tenglisong lncrnauca1inanticancerdrugresistance